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ABSTRACT
Because of its life cycle, the recovery of Toxoplasma gondii from biological samples is often impracticable.
Consequently, a serological diagnosis represents the first and the most widely used approach to defining
the stage of infection. The detection of IgG, IgM, IgA, IgE and IgG avidity by different methods offers
this opportunity. However, the results may be affected by difficulties in interpretation, as the same
antibody pattern may have a different valency, contingent upon subjects and clinical settings, e.g.,
pregnant women vs. neonates, and treated vs. untreated patients. This review describes the various
factors that should be taken into account when performing serological tests for T. gondii, as well as the
pitfalls that may be encountered during the interpretative process.
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INTRODUCTION
Approximately one-third of the world’s popula-
tion is infected by Toxoplasma gondii, an obligate
intracellular protozoan belonging to the phylum
Apicomplexa, subclass Coccidia. The infection
can be acquired by eating raw meat containing
tissue cysts, or food and water contaminated by
oocysts. The clinical manifestation is usually
benign in immunocompetent hosts, but can be
life-threatening in an immunocompromised pa-
tient. Diagnosis of toxoplasmosis can be achieved
by demonstrating the parasite in biological
samples or by detection of specific antibodies.
Molecular diagnosis by PCR has reduced greatly
the time required to determine the presence of
parasites when compared with the time required
following mouse or tissue culture inoculation.
PCR amplification of the 35-fold repetitive B1
gene has been used successfully to diagnose
congenital infection. Real-time PCR and other
gene targets will probably be used in the future,
but serological tests to determine specific anti-
bodies are currently the first-line method of
diagnosis for current, recent or past infection.
Since the medical history may not be informative,
all test results must be considered to represent
parts of a puzzle, where each piece has its own
special significance. Some pieces often seem out
of place, so that the final interpretation can be
achieved only when the puzzle is considered as a
whole.
The diagnosis of primary infection during
pregnancy and the diagnosis of congenital infec-
tion are the most challenging situations. First, the
pitfalls hidden in the serological responses can
make the interpretation problematic. Simulta-
neous testing for specific IgG and IgM in serial
serum samples collected at an interval of 3 weeks
is the initial approach in screening for T. gondii
infection. Successive tests, and the conclusive
diagnosis, will depend on these initial results.
Second, the immunological markers can vary
depending on the trimester of infection, and
maternal and neonatal therapeutic treatment dur-
ing pregnancy can block or retard the immune
response of the neonate. An approved guideline
for the interpretation of serological tests was
published by CLSI (formerly NCCLS) in 2004
[1], and updates of recent developments in the
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diagnosis and management of toxoplasmosis in
different clinical settings have also been pub-
lished [2,3]. The present review considers the
occurrence and significance of different serolog-
ical patterns in pregnant women and in congen-
itally infected neonates.
IgG- AND IgM-NEGATIVE
Pregnant women
An individual is considered susceptible to infec-
tion when specific antibodies are not detected in
serum samples. Therefore, women of childbearing
age are at risk for acquiring primary infection,
and pregnant women require regular checks for
seroconversion. The frequency of these checks
varies, depending on the screening programmes
adopted in different countries. Maternal monitor-
ing usually ceases during the third trimester or
just before delivery. However, infection could be
acquired at the very end of pregnancy, with the
mother still seronegative at delivery. The rate of
transmission from mother to foetus is > 70%
during this period [4], and the neonate will be
infected without any clinical symptoms at birth.
In the absence of prompt and appropriate thera-
peutic treatment, the neonate can develop late
sequelae [5–8]. Armstrong et al. [9] reported a case
of severe neonatal toxoplasmosis, demonstrated
by positive IgG, IgM and placental tissue PCR
results, in a neonate whose mother remained IgG-
and IgM-negative in repeated serum samples.
This finding was intriguing, given that there was
no evidence of maternal illness as a possible cause
of this negative serology [9]. In our own experi-
ence [10], a woman aged 32 years, who was IgG-
and IgM-negative until the eighth month of
pregnancy, was found to be IgM-positive by
ELISA at 10 days before delivery. Three days
later, IgM was positive by an immunosorbent
agglutination assay (ISAGA), with a positive IgA
result by ISAGA at delivery. Ten days after
delivery, IgG appeared in serum (50 IU ⁄mL).
Congenital toxoplasmosis was diagnosed in the
neonate (IgM- and IgA-positive by ISAGA at
birth, and an IgG titre of 40 IU ⁄mL after 8 days).
The infant, who was completely asymptomatic,
received appropriate treatment until aged 1 year.
At present, our protocol recommends a further
serological check after delivery for all seronega-
tive pregnant women.
Congenital infection
A negative serological pattern can be a transitory
phenomenon in congenital toxoplasmosis as a
consequence of maternal and neonatal treatment,
particularly when the maternal infection occurred
during the first two trimesters of pregnancy
[11,12]. In such cases, the initial diagnosis of
congenital toxoplasmosis should not be ques-
tioned, and treatment and routine monitoring
should be continued. Frequently, the transitory
negative period is followed by a serological
rebound, often after the cessation of therapy.
The consequent rise in antibody titres has not
been associated with increased risk for the child,
and additional courses of treatment and enhanced
ophthalmological surveillance do not seem to be
warranted [13].
IgG-NEGATIVE AND IgM-POSITIVE
Pregnant women
IgM antibodies are characteristic markers of acute
infection. They appear at the onset of infection
and persist for variable periods, but their time-
dependent detection is determined by the sensi-
tivity of the test. Numerous tests are now
available commercially. In immunocompetent
subjects, IgG production follows IgM production
at different times, according to the diagnostic
methods used. When seroconversion occurs, the
diagnosis of primary infection is confirmed.
Pregnant women are sometimes seropositive
only for IgM, and IgG may not be detected during
the serological follow-up. These natural IgM
antibodies are believed to react with toxoplasma
antigens in the absence of infection. Natural
antibodies are predominantly of the IgM class
[14], and only occasionally of the IgG class [15],
and vary greatly following electrophoretic exam-
ination [16]. They are found rarely in neonates and
infants aged < 6 months. In pregnant women they
can be present for the whole gestation [17], or for
only a limited period [18]. In such cases, because
of the slow increase in IgG titres observed with
conventional ELISAs, it is advisable to employ
additional tests with the use of the whole parasite
as an antigen, e.g., dye tests, indirect immunoflu-
orescence assays or agglutination tests [19].
A sudden IgM seropositivity during the course
of pregnancy should alert the physician to start
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therapeutic treatment before confirmation of the
infection (seroconversion) in an attempt to
prevent transmission to the foetus. However,
therapeutic treatment, particularly with pyri-
methamine and sulphadiazine, may block the
production of IgG (personal unpublished results).
In such a case, the serological pattern may remain
unchanged.
It is worth mentioning that a peak of IgA
antibody production occurs following primary
infection, shortly after the detection of IgM. Since
IgA is not considered to be naturally occurring,
the concurrent presence of IgM and IgA denotes
primary infection.
Congenital infection
As discussed above, detection of IgM, but not
IgA, can occur at birth in the case of very late
maternal infection during pregnancy. IgA and
IgG are usually detected in subsequent serum
samples. In the case of IgM and ⁄ or IgA detection
in the neonate, the test should be repeated
c.10 days after birth in order to exclude contam-
inating maternal antibodies [20].
IgG-POSITIVE AND IgM-NEGATIVE
Pregnant women
Detection of IgG without IgM defines the classi-
cal serological pattern of past infection. An
immunocompetent pregnant woman with sero-
logically demonstrated chronic (or latent) infec-
tion at the beginning of pregnancy is not
considered to be at risk for giving birth to a
neonate with congenital infection [5]. In the third
trimester, a negative IgM titre probably reflects
past infection, but does not exclude an acute
infection early in pregnancy. This can occur in
some patients exhibiting a rapid decline in IgM
titre. In such cases it is advisable to use other
tests, e.g., IgA and IgG avidity, as described
below. A few cases of infected offspring born
from previously immune mothers have been
described [21–26], but these are regarded as
exceptions. Interestingly, in some cases, IgA anti-
bodies were also present. Since these immuno-
globulins are produced during the digestive
phase of acute infection, it has been suggested
that reinfection was probably linked to accidental
ingestion of oocysts from a different or partic-
ularly virulent strain following maternal contact
with kittens [21–23].
As mentioned above, naturally occurring IgG
can be present, albeit rarely. Our own experience
has included five probable cases of natural IgG.
IgG was detected in three of these during the first
trimester, in one during the second, and in one
during the third. Several serial serum samples
were collected for the detection of IgM and IgA
(ISAGA test) and for the IgG avidity test. IgM and
IgA antibodies were always negative, and the IgG
avidity value was low in two cases, intermediate
in one case and high in the remaining two cases.
Three women were treated with spiramycin.
Following birth, the neonates showed the same
western blot profile and IgG levels as their
respective mothers. All children were seronega-
tive at the last check (aged 1 year) without any
treatment (personal unpublished results).
Congenital infection
At birth, the detection of IgG without any other
positive serological marker is indicative of either:
(i) congenital infection after maternal infection
during the first or second trimester of pregnancy;
(ii) infection of neonates whose mothers have
been treated during pregnancy; or (iii) non-infec-
tion. In the case of early maternal acquisition, the
neonate could be at the end of the sub-acute stage
of infection, at which time the production of IgM
and IgA has already occurred. In the case of
maternal infection during the second trimester,
IgA can be detected in the absence of IgM because
of the longer persistence of IgA compared with
IgM in the neonate (contrary to what is observed
in adults). However, it is advisable to test serum
samples from the neonate for IgA, given the
higher sensitivity of this class of immunoglobulin
as a marker for congenital infection [27–30]. In the
case of IgA detection in the neonate, the test
should be repeated c.10 days after birth in order
to exclude contaminating maternal antibodies
[20].
In the case of suspected maternal infection
and consequent therapeutic treatment, the fetal
immune response can be blocked or retarded,
with a consequent delay in the production of
predictive serological markers. Persistence or
increase of IgG during the first year of life
remains the most reliable way of diagnosing
congenital infection, but this procedure is
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time-consuming. If IgG antibodies only are
detected, it is crucial to distinguish whether
they are of maternal origin and have been
transmitted passively, or whether they represent
de-novo synthesis by the congenitally infected
foetus. In the latter case, therapeutic treatment
should be initiated as soon as possible following
birth to prevent late sequelae.
The immunoblotting method has been used
successfully to compare antibody reactivity in
mother and child for diagnosis of congenital
toxoplasmosis [31]. This method combines elec-
trophoresis of toxoplasma antigens under denat-
urating conditions with a specific antibody test.
The study of T. gondii antigens by western blotting
has allowed the identification of immunodominant
antigens, as well as the identification of stage-
specific antigens for use in serological assays [32–
34]. The strain-specific antigenic differences
detected help to explain the different electropho-
retic patterns observed among different subjects
[35]. The definition of positivity is based on the
presence of at least one IgG-reactive antigen in
the sample from the child, and its absence in the
corresponding sample from the mother. A
moderate variability has been observed among
studies. However, the method has not been
standardised, and antigen preparation, gel condi-
tions, dilutions of patient sera, and sources of
secondary antibody are not yet defined. Never-
theless, some applications have been semi-auto-
mated by a computer program, which makes
reading the intensity of the bands easier and gives
greater reproducibility. The best results in terms
of sensitivity have been obtained when the
method has been used for detection of IgM and
IgA, as well as IgG, in combination with standard
methods.
Chumpitazi et al. [36] evaluated the immuno-
blot method in comparison with other conven-
tional tests, including mouse inoculation and
in-vitro culture of the parasite, for pre-natal,
at-birth and after-birth diagnosis of congenital
toxoplasmosis. It was concluded that for at-birth
diagnosis, immunoblot analysis of IgG, IgM and
IgA reached a sensitivity of 92.6%, with a specif-
icity of 89.1%. Analysis of the electrophoretic
bands showed antibodies directed against anti-
gens with high and low molecular sizes (18 000–
185 000 kDa), although most were in the 18 000–
135 000 kDa range [36]. Gross et al. [37] focused
their attention on IgG detection, reporting a
sensitivity of 82.4%, a specificity of 93.0%, a
positive predictive value of 73.7%, and a negative
predictive value of 95.7%. The immunodominant
Toxoplasma antigen SAG1 ⁄P30 was not recognised
preferentially in child serum samples. In nearly
all cases of congenital infection, the child devel-
oped IgG against at least two antigens, and all of
the IgG-reactive antigens were consistently
> 30 kDa. It was suggested that two samples
should be collected, at birth and 4–6 weeks later,
to confirm the diagnosis [37]. In a collaborative
study for post-natal diagnosis of congenital infec-
tion, Pinon et al. [38] compared immunoblotting
and enzyme-linked immunofiltration assay (ELI-
FA) with standard methods for IgG, IgM and IgA
detection during the first year of life. In the case of
treatment in utero, and after treatment of the child
for 1 year with pyrimethamine and sulphona-
mides, congenital infection was not detected. In
these individuals, immunological markers were
detected only when treatment was withdrawn,
owing to a rebound of anti-Toxoplasma antibodies.
Combining commercial western blot assays with
conventional serological analyses at birth and
within the first 3 months, 94% of congenital
infections were detected [39]. A two-dimensional
immunoblotting method to improve the differen-
tiation of mother and child IgG profiles has been
proposed [40].
IgG- AND IgM-POSITIVE
Pregnant women
One of the most challenging situations occurs
when IgG and IgM are positive and the serolog-
ical status before pregnancy is unknown. The
collection of a second serum sample after 3 weeks
is recommended, but meaningful differences in
IgG and IgM titres are observed rarely. IgG titres
can show great variability among individuals,
and even a high titre, e.g., IgG ‡ 300 IU ⁄mL in a
dye test, cannot be used as a diagnostic criterion
for recent primary infection because of its low
sensitivity [41]. A positive IgM result can be
interpreted as: (i) a true-positive result indicating
recently acquired infection; (ii) a true-positive
result indicating past infection; or (iii) a false-
positive result [20]. Many commercial products
for IgM detection have been studied extensively
and compared for sensitivity and specificity [42–
45], but since there is no accepted reference
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standard, parameters of test accuracy are poorly
defined. The specificity and positive predictive
value of new assays are related directly to the
prevalence of negative and positive samples,
respectively, as detected by the reference test.
Therefore, the selection of sera used for evalua-
tion influences the accuracy of the test markedly
[46]. Several groups of investigators are working
to find specific antigens and ⁄ or to produce
recombinant antigens to improve the performance
of IgM assays [47–53].
IgM can be detected for a long period following
the acute infection, and therefore a true-positive
result cannot discriminate between acute, recent
and past infection. Timing the onset of the
infection is crucial in pregnant women, especially
because post-conceptional acquisition represents
a risk for the foetus. For this purpose, other
diagnostic tools can be utilised, such as IgA and
IgG avidity detection. IgA antibodies appear
shortly after IgM and persist for some time
(usually 6–7 months) after the onset of infection.
IgA-ISAGA is the more sensitive assay [54–57].
However, IgA has been detected for > 1 year in
some subjects, but is never detected in a small
percentage of acute infections [58]. Therefore, a
negative IgA result does not exclude an acute
infection, and a positive IgA result does not
necessarily indicate an acute infection.
IgE antibody detection has been proposed as a
way of defining the stage of infection [59–62],
because IgE is found only in serum samples from
patients with acute infection, and the duration of
IgE seropositivity is shorter than that of IgM and
IgA. Enzyme immunoassays (EIAs) and ISAGA
tests have been used for IgE determination, but
these assays are home-made and have been
applied in only a few reference centres. However,
Foudrinier et al. [63] showed limited (a few
months) IgE seropositivity in 85.7% of asympto-
matic seroconverters, and long persistence at a
very high titre in 100% of seroconverters with
overt toxoplasmosis. Furthermore, IgE emerged
concomitantly with the increase of IgG during
reactivation [63].
Since its introduction [64], many studies have
been published concerning the use of the IgG
avidity test to discriminate between recently
acquired and past infections by employing nat-
ural [65,66] or recombinant antigens [67], as well
as its adaptation to automated systems [68,69].
The functional affinity of specific IgG antibodies is
initially low after primary antigenic challenge, but
increases during subsequent weeks and months
by antigen-driven B-cell selection. Protein-dena-
turing reagents, including urea, are used to
dissociate the antibody-antigen complex. The
avidity value is determined by using the ratios
of antibody titration curves for urea-treated and
untreated samples. The maturation of IgG avidity
has been studied by monitoring subjects with
seroconversion or with typical clinical manifesta-
tions: high-avidity results exclude Toxoplasma
infection during the preceding 3–5 months.
The length of time required for conversion from
low- to high-avidity antibodies depends on the
method used. In pregnant women, a high-avidity
test is highly predictive of past infection if
performed in the first trimester. Low or border-
line IgG-avidity antibodies are known to persist
for > 1 year and, for this reason, are not reliable
for diagnosis of recently acquired infection. Fur-
thermore, it has been suggested that antibiotic
treatment can modify the maturation of IgG
avidity [70,71], although discordant results have
been reported occasionally [72].
Congenital infection
IgM detection in neonatal serum samples is
indicative of congenital infection. However, the
test should be repeated 10 days after birth to
exclude contaminating maternal antibodies. An
ISAGA is more sensitive than an EIA in defining
congenital infection. This serological pattern pre-
sumes that maternal infection was acquired in the
third trimester if IgA is also detected, or in the last
month of pregnancy if IgA is still not present.
IgE has been found in serum samples from
congenitally infected neonates, but the sensitivity
of IgE detection is lower than that of IgM and IgA
[73]. Emergence of specific IgE during post-natal
treatment is considered to be a sign of poor
adherence or inadequate dosing [63]. Neverthe-
less, simultaneous measurement of IgM, IgA and
IgE improves the diagnostic yield. As for IgM and
IgA, a positive test should be repeated c.10 days
after birth to exclude contaminating maternal
antibodies.
IgG avidity is generally not evaluated in the
neonate, because it is similar to that of the mother.
However, it has been observed that, in the
absence of maternofetal transmission, the avidity
index remains stable until the disappearance of
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passively transmitted maternal antibodies. In
contrast, the IgG avidity index shows a significant
increase in congenitally infected children. In
addition, long-term therapy with pyrimetham-
ine-sulphonamide, as opposed to treatment with
spiramycin alone, was found to slow the progres-
sion of the avidity index [72]. A delayed matur-
ation of IgG avidity in congenital toxoplasmosis
has been reported by Buffolano et al. [74]. These
authors demonstrated the feasibility of perform-
ing the test on antibodies eluted from dried blood
spots (Guthrie cards), making it possible to detect
at birth a maternal primary infection acquired
during the second or third trimester of gestation,
and to evaluate retrospectively the risk for con-
genital infection when suspicion of congenital
infection arises during late infancy [74].
Tables 1 and 2 summarise the serological pat-
terns discussed in the previous sections.
CONCLUSIONS
Important progress has been made in acquiring
knowledge concerning the antigenic and genomic
structure of T. gondii. Adjunctive tests are now
available that will allow a better definition of the
stage of infection. Pelloux et al. [75] show that
definition is very easy in the presence of serocon-
version or persistent negative serology, but the
challenge is to interpret the detection of specific
IgM in pregnant women. The demonstration of a
significant rise in antibody titres in serial serum
samples obtained at least 3 weeks apart and run
in parallel is probably the standard, but precious
Table 1. Serological patterns in pregnant women infected with Toxoplasma gondii
Serological pattern Interpretation Comments Advice References
IgG- IgM- Susceptibility Risk for primary infection Risk for maternal infection at the
end of pregnancy
[7-9]
IgG- IgM+ (a) Onset of infection Primary infection. Risk for
congenital infection
Collect second serum sample 2-3 weeks apart
and test in parallel to demonstrate seroconversion
[1-3,19]
(b) Natural antibodies No risk for congenital infection Collect serial serum samples and test in parallel
to exclude seroconversion
[14-18]
(c) False-positive No risk for congenital infection Collect serial serum samples and test in parallel
to exclude seroconversion
[1-3]
IgG+ IgM- Past infection No risk for congenital infection Take natural IgG antibodies into account
Rare congenital infections
[15] [21-26]
IgG+ IgM+ (a) Past or recently
acquired infection
Risk for congenital infection Take gestation period into account. Test for IgA, IgE and IgG
avidity in a reference laboratory
[1-3]
(b) False-positive No risk for congenital infection Test for IgA, IgE and IgG avidity in a reference laboratory [1-3]
+,), indicates the presence or absence of antibodies.
Table 2. Serological patterns in neonates infected with Toxoplasma gondii
Serological pattern Interpretation Comments Advice References
IgG- IgM- (a) Susceptibility No congenital infection
(b) Transient
seronegativity
Congenital infection Take maternal and ⁄ or in-utero treatment and
possible serological rebound after therapy
cessation into account
[11-13]
IgG- IgM+ (a) Maternal IgM No congenital infection Collect second serum sample 10 days after birth
to confirm contaminating maternal antibodies
[20]
(b) Neonatal IgM Congenital infection after very
late maternal infection
Collect serial serum samples to demonstrate
seroconversion
[5]
IgG+ IgM- (a) Maternal antibodies No congenital infection Serological follow-up for 1 year to confirm
IgG negativity
[5]
(b) Maternal and neonatal Congenital infection after Test for IgA, more lasting than IgM. [27-30]
antibodies maternal infection in the
first or second trimester
Differentiate maternal and3 neonatal IgG by
WB or ELIFA
[31-40]
IgG+ IgM+ (a) Maternal antibodies No congenital infection Collect second serum sample 10 days after birth
to confirm contaminating maternal IgM antibodies.
Test in parallel maternal and neonatal IgG by WB or
ELIFA. Serological follow-up for 1 year to confirm IgG
negativity. Check for stable IgG avidity index
[20] [31-40] [5] [72,74]
(b) Maternal and neonatal
antibodies
(b) Congenital infection after
maternal infection in the
third trimester (IgA+) or
in the last month (IgA))
Collect second serum sample 10 days after birth to exclude
contaminating maternal IgM antibodies. Test in parallel
maternal and neonatal IgG by WB or ELIFA. Serological
follow-up for 1 year to demonstrate IgG persistence.
Check for increased IgG avidity index
[20] [31-40] [5] [72,74]
+,), indicates the presence or absence of antibodies.
WB, western blot; ELIFA, enzyme-linked immunofiltration assay.
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time can be lost in initiating therapeutic treatment
to prevent transmission and ⁄ or to limit damage to
the foetus. At this time, the results of new
serological tests should be added to the puzzle
and referred to a reference laboratory. The bene-
fits derived from this strategy have been demon-
strated by Liesenfeld et al. [76], who reported a
decrease in unnecessary abortions for c.50% of
women with positive IgM tests performed at
peripheral laboratories, once confirmatory tests
had been performed in a reference laboratory and
the correct interpretation given to the patient’s
physician. However, serology represents only a
branch of the complex immunological response of
the host to T. gondii infection.
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